Pyoderma caused by methicillin-resistant Staphylococcus pseudintermedius poses significant challenges to canine health. Successful therapy requires an integrated approach to prudent antimicrobial use. This report describes the successful treatment of a dog with generalised superficial pyoderma using a topical formulation of S. pseudintermedius phage applied once daily for a period of 30 days.
Background: Canine atopic dermatitis (cAD) varies in prevalence and lesion distribution across breeds. In contrast to Western countries, many Asian countries favour small-to-medium dog breeds. However, previous studies have focused primarily on medium-to-large dog breeds.
Objectives: To analyse the prevalence and lesion distribution of cAD in common breeds in Korea, focusing on breed-specific characteristics.
Animals: Nine small-to-medium breeds (<25 kg body weight) were selected from 331 client-owned dogs with cAD, representing 77% of the total cAD group.
Materials and methods: Breeds selected included Maltese, miniature/toy poodle, shih tzu, bichon frise, cocker spaniel, Pomeranian, French bulldog, Yorkshire terrier and Dachshund. The prevalence of these breeds was compared to the registered dog population. Photographs of skin lesions from each dog were reviewed, and the lesion distribution was analysed by breed.
Results: Shih tzu, cocker spaniel and French bulldog had a higher prevalence of cAD compared to the registered dog population (p < 0.01). Lesions were most commonly present on the ventral aspects of the body in 51% of shih tzus; lip folds (64%), tail folds (27%) and paws (73%) in French bulldog; and 71% of Dachshunds had dorso-lumbar distribution.
Conclusions and clinical relevance: Of the small-to-medium breeds in this study, shih tzu, cocker spaniel and French bulldog had a higher prevalence of cAD compared to the registered dog population, while specific body sites were affected in shih tzu, French bulldog and Dachshund.
Background: Canine atopic dermatitis (cAD) is a chronic inflammatory and pruritic dermatopathy requiring a multimodal therapeutic approach.
Objective: To assess the effectiveness, safety and cost of oclacitinib and prednisolone treatment in dogs with AD.
Animals: Twenty-three client-owned dogs with cAD.
Materials and methods: Dogs were randomly assigned to one of two groups: Group 1 received prednisolone (0.5 mg/kg every 24 h) for 7 days, then oclacitinib (0.5 mg/kg) and prednisolone (0.5 mg/kg), were administered alternately with a 1 day pause between each drug, for 7 additional weeks. Group 2 received oclacitinib (0.5 mg/kg every 12 h for 14 days, then every 24 h) for 8 weeks. Assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (PVAS) on Day (D)0, D7, D14, D30, D45 and D60.
Results: Both groups showed significant CADESI and PVAS reductions on D7 (p < 0.001). From D14 to D60, mean scores remained stable compared to D7, with no significant differences between groups. Adverse events included two dogs with polyuria and polydipsia, and three with polyphagia in Group 1, all of which resolved by D14. In Group 2, one dog experienced polyphagia, and two had self-limiting vomiting. Three dogs in Group 1 and one dog in Group 2 had mild increases in liver enzyme concentrations.
Conclusions and clinical relevance: The combined protocol was effective and safe for managing itch and inflammation over a 60 day period. It had a 73.3% lower cost compared to oclacitinib alone.
Background: Demodicosis is common in dogs and is caused by proliferation of commensal Demodex canis mites.
Objective: To evaluate the efficacy of sarolaner in combination with moxidectin and pyrantel (SMP) for the treatment of generalised demodicosis in dogs.
Animals: One hundred and thirty dogs with generalised demodicosis.
Materials and methods: In two separate randomised masked studies (laboratory and field studies), dogs received monthly oral SMP or afoxolaner + milbemycin oxime (AM). In the laboratory study, dogs received three monthly treatments with biweekly mite counts and clinical evaluations. In the field study, mite counts and clinical evaluations were performed monthly and treatments were administered until two consecutive skin scrapings were negative.
Results: Both products were tolerated well. In the laboratory study, mite counts for SMP were significantly (p < 0.001) reduced by 88.8% on Day (D)14, by 99.2% on D29, and no live mites were detected thereafter with no statistically significant difference (p = 0.96) between the two treatment groups. In the field study, SMP provided 92.4%, 98.1%, 100% and 100% reduction in arithmetic mean live mite counts on D30, D60, D90 and D120, and was non-inferior to the control product on D30 and D60. Clinical signs of demodicosis improved in all dogs.
Conclusions and clinical relevance: Monthly administration of SMP was effective for the treatment of generalised demodicosis in dogs as it eliminated Demodex mites after two monthly treatments in the laboratory study, and at most after three monthly treatments in the field study.
Background: Hospital-related dermatological conditions are well-studied and reported in human medicine. However, studies about these dermatological disorders in veterinary medicine are lacking.
Objectives: To report the incidence, type and distribution of hospital-acquired skin lesions (HASL) in dogs, and to investigate risk factors that may be associated with their development.
Animals: Hospitalised client-owned dogs with HASL and a control group of hospitalised dogs without skin lesions.
Materials and methods: Prospective clinical evaluation of all HASL and dermatological tests, when indicated, were performed, over 6 months. A variety of potentially predisposing factors also were recorded.
Results: Thirty-one dogs with HASL and a matched control group of 60 hospitalised dogs without skin lesions were included. The incidence of HASL was 11.2% (31 of 278). The most common lesion was erythema in 74.2% of dogs (23 of 31) and the most affected area was the abdomen in 58.1% (18 of 31) of dogs. Faecal and/or urinary incontinence was identified as an important risk factor for the development of skin lesions during hospitalisation (odds ratio 14.445, 95% confidence interval 1.444-144.479, p = 0.023). Immobilisation and changes in body temperature also may play a role in the development of such lesions in dogs.
Conclusions and clinical relevance: Faecal and/or urinary incontinence was found to be an important factor in the development of HASL. The impact of HASL on patient outcomes and the prevention of these lesions requires further investigation.
Feline paraneoplastic alopecia is associated with intraabdominal neoplasms. A 13-year-old female cat was presented with a history of a cutaneous mass on the head, followed by ventrally distributed alopecia with shiny skin. Necropsy revealed an apocrine adenocarcinoma and telogenisation/miniaturisation of the hair follicles, respectively. These findings are consistent with paraneoplastic alopecia.
Canine exfoliative cutaneous lupus erythematosus (ECLE) is the rarest variant of cutaneous lupus in dogs and has strong breed predilections. This report presents the clinical, histopathological and immunohistochemical features of two ECLE cases in mixed breed littermates and confirms the expected genetic mutation. A therapeutic response to oclacitinib also is documented.
Background: Intradermal allergen testing (IDAT) is commonly used to formulate allergen-specific immunotherapy, a pillar treatment for canine atopic dermatitis. Many sedatives have shown histaminergic or anti-histaminergic effects and thus been deemed unsuitable for IDAT.
Objective: The goal of this study was to determine whether, in healthy dogs, dexmedetomidine (Dexdomitor) or a 1:20 combination of medetomidine and vatinoxan (Zenalpha) will affect intradermal reactions compared to unsedated dogs.
Animals: Ten privately owned healthy dogs were enrolled in this equivalence study.
Materials and methods: Wheal formation was subjectively and objectively assessed in conscious then sedated dogs. Dogs were randomly sedated with either Dexdomitor (dexmedetomidine [0.5 mg/m2]) or Zenalpha (medetomidine [1 mg/m2/vatinoxan] 20 mg/m2) intramuscularly. Once sedated, five 10-fold histamine (100-0.01 μg/mL) and compound 48/80 (200-0.02 μg/mL) dilutions were intradermally injected into the lateral thorax. The study was repeated on the opposite side with the alternative sedation 1 week later. Quality of sedation, cardiorespiratory function and rectal temperature were recorded every 5 min.
Results: There was no difference in the median values of the reactions with either sedative when compared to unsedated dogs. Dexdomitor and Zenalpha achieved an equivalence in both subjective and objective scoring systems for all concentrations tested. A faster median time to sedation (10 vs. 18 min, p = 0.013) was seen with Zenalpha compared to Dexdomitor. Although both sedatives depressed the cardiovascular function, such parameters were less affected by Zenalpha than by Dexdomitor (p ≤ 0.001).
Conclusions and clinical relevance: Owing to the lack of effects on wheal formation, both sedatives are appropriate for sedating dogs undergoing IDAT. Although, such results should be validated in allergic dogs. Zenalpha may induce more rapid and reliable sedation than Dexdomitor.
Background: Anal sac impaction is common in dogs. Manual expression may be effective, yet recurrence can be problematic. To facilitate physiological emptying of the sacs, it is important to maintain bulky stool consistency.
Objectives: The study evaluated if supplementation with a complementary feed product formulated as a chew containing Bacillus velezensis C-3102 and fibre sources, reduced anal sac impaction recurrence.
Animals: Thirty-five client-owned dogs with anal sac impaction were enrolled.
Materials and methods: Prospective, randomised, negative controlled field clinical trial with 22 dogs receiving the chew orally for 90 consecutive days and 13 dogs with no treatment. Dogs were evaluated on Day (D) 30, 60, 90 and 120 for the presence of clinical signs of anal sac impaction and the need to empty the sacs. Any animal that required manual expression of the sacs was classified as a failure and was withdrawn from the study.
Results: The cumulative percentage of failures in the untreated group increased steadily from the first follow-up visit on D30 (15%) to the last visit on D120 (61.5%). However, in the group receiving the chew the cumulative percentage of failures increased at a much slower rate and stabilised at 19% from the D90 visit (last administration day) until the end of the study on D120, with statistically significant differences (p = 0.025). Animals receiving the chew also showed reduction in clinical signs.
Conclusion and clinical relevance: The probiotic and fibre chew was a safe and effective management option for recurrent anal sac impaction in dogs.
Background: Canine superficial pyoderma is a common bacterial skin infection of dogs, generally caused by Staphylococcus pseudintermedius. The C4 strain of Staphylococcus felis was recently discovered to have strong antimicrobial activity against S. pseudintermedius in mice.
Objectives: We aimed to evaluate in vitro if this antimicrobial activity was maintained using a novel canine skin explant model.
Materials and methods: Punch biopsies (8 mm) of skin from recently euthanised dogs were collected and placed into six-well plates on top of an agarose pedestal.
Results: Histological examination of the skin explants showed an intact dermal-epidermal organisation and a stratum corneum that was successfully colonised by S. pseudintermedius after topical application. The number of colony forming units of S. pseudintermedius showed a 2 log increase after 24 h colonisation, indicating that the explant supported bacterial growth. By contrast, co-treatment with S. felis C4 live bacteria and its sterile protein product significantly reduced the growth of a methicillin-susceptible (ST540, p = 0.0357) and a methicillin-resistant (MR) strain (ST71, p = 0.0143) of S. pseudintermedius. No detectable bacteria were recovered from or visualised on skin 24 h posttreatment with the S. felis C4 sterile protein product.
Conclusions and clinical relevance: Using a novel canine explant model, we demonstrate that the S. felis C4 strain inhibits the growth of S. pseudintermedius and that it is a promising candidate for a new probiotic therapy to treat cutaneous infections caused by S. pseudintermedius, including MR strains.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：